NRXP
NRX Pharmaceuticals Inc
2.90$
+1.9%
vs. previous close
Closing price · As of: Oct 2, 2026
Statements
Cash Flow
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | -50.0% | +0.0% | +0.0% | +100.0% | -50.0% | +0.0% | -200.0% | – | +132.6% | +65.0% | +4.8% | – | |
| – | -442.7% | – | -59.9% | +7.2% | -58.7% | -72.1% | +458.3% | +1.5% | +19.1% | +86.4% | -7.9% | – | |
| – | +198.3% | -5.6% | -8.0% | -83.3% | -124.4% | – | – | – | +139.5% | -75.6% | -1,140.8% | – | |
| – | +100.0% | -75.0% | -100.0% | – | – | – | – | – | – | – | – | – | |
| – | – | – | – | – | – | – | – | – | -90.3% | -14.5% | +221.1% | – | |
| – | – | – | – | – | – | +429.4% | -91.9% | -252.1% | – | -100.0% | – | – | |
| – | -25.6% | – | +933.9% | -49.7% | -7.7% | +300.3% | -81.7% | +599.7% | -53.0% | -25.2% | +762.5% | – | |
| – | – | – | – | -143.5% | – | – | -164.3% | – | -85.7% | -276.8% | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: October 2, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.